Fox Business - The Power to Prosper
Search Site

Actelion Pharmaceuticals

MARKET COMMENT: Zurich Stocks Close Slightly Higher

1703 GMT [Dow Jones] SMI closes slightly higher, up 0.4% at 7074.52, boosted by the pharmaceutical sector and defensive stocks. Actelion is the day's biggest climber, gaining 3.4% on positive comments by its CEO, Jean-Paul Clozel, ahead of an investor meeting. Also supporting gains in the index are increases by heavyweights Roche, up 1.3%, and Novartis, up 0.6%. Elsewhere on the index, cyclical stocks dip slightly, following disappointing German industrial-order data and unemployment figures from the euro zone. Building supplies company Geberit, which has Germany as its largest market, is the day's biggest loser, dropping 0.9%. (john.revill@dowjones.com)Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.comSubscribe to WSJ: http://online.wsj.com?mod=djnwiresCopyright © 2013 Dow Jones Newswires...

Read More

  1. J &J must pay Basilea $130 million for drug license breach

    By Katie ReidZURICH (Reuters) - Johnson & Johnson <JNJ.N> must pay former Swiss partner Basilea <BSLN.S> about $130 million for breaching a license agreement for a s...

  1. Merck Plans To File Insomnia Drug Application To FDA In 2012

    Merck & Co. (MRK) said Monday that it plans to apply this year for U.S. regulatory approval to market a potential new treatment for insomnia, based on positive clini...

  2. Insight: Why Swiss medicine men swallow a strong franc

    By Katie Reid and Ben HirschlerBASEL (Reuters) - In recent months, a red-hot Swiss franc has made Switzerland an expensive place to buy a slice of pizza, let alone r...

  3. Company value creation? Could do better

    By Christopher Vellacott and Victoria HowleyLONDON (Reuters) - Long-term investors are losing patience with companies that fail to maximize value as the slowing reco...

  4. Roche raises 2011 earnings goal as cuts kick in

    By Katie ReidZURICH (Reuters) - Swiss drugmaker Roche Holding AG <ROG.VX> raised its full-year earnings target for 2011 on Thursday as cost-cutting protected its fir...

  5. Pressure on Actelion rises after Asahi case decision

    By Katie ReidZURICH (Reuters) - Swiss biotech group Actelion Ltd <ATLN.VX> is now facing a tougher battle at its annual general meeting next week after a jury decide...

  6. Takeover Talk Boosts Actelion After Drug Disappoints

    ZURICH -(Dow Jones)- Renewed takeover speculation helped shares in Actelion Ltd (ATLN.VX) recover Friday after Europe's largest biotech company said it was discontin...

  7. Sleeping Pill Discontinuation Latest Blow For Actelion

    ZURICH -(Dow Jones)- Actelion Ltd (ATLN.VX) Friday said it was discontinuing the development of its potential multi-billion dollar blockbuster sleeping pill almorexa...

Freebase CC-BY
Source: Actelion Pharmaceuticals on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL